Adding empagliflozin to ongoing metformin improves metabolic profile, tg-g and fib-4 indexes and liver function tests in type 2 diabetic patients with NAFLDS, a clinical trial
Abstract
ABSTRACT Background SGLT2 inhibitors offer strong glucose-lowering effects in patients with T2DM, but their impact on MAFLD when added to ongoing metformin therapy is not fully understood. This study aimed to evaluate the effects of empagliflozin (a SGLT2 inhibitor) on metabolic profile, liver fibrosis index, and liver function tests in metformin-treated T2DM patients with MAFLD. Research design and methods This 12-week, prospective, single-center clinical trial enrolled 80 T2DM patients with MAFLD who were already receiving metformin but required further intervention. They received empagliflozin (10 mg/day) in addition to metformin (2000 mg/day). Metabolic parameters including FBS, HbA1c, Chol, TG, LDL, HDL, vitamin D3, ALT, ALP, and AST were measured at baseline and after 12 weeks. Triglyceride-glucose (TG-G) index and fibrosis-4 (FIB-4) score were also calculated. Results Seventy-four patients completed the trial. Significant reductions were seen in FBS, HbA1c, Chol, LDL, TG, and TG-G index (p < 0.001). Liver markers ALT, AST, and FIB-4 also improved significantly (p < 0.001 and p < 0.02, respectively). Although HDL, ALP, and vitamin D3 increased, these changes were not statistically significant. Conclusion Adding empagliflozin to ongoing metformin significantly improved metabolic and liver-related markers in T2DM patients with MAFLD, supporting its therapeutic benefit in this population (Clinical Trial Registration: https://irct.behdasht.gov.ir/trial/73164).
How strong is the evidence?
Evidence Hub reads this as a clinical trial, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 80 participants or records.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.